help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aris, R. M.
Right arrow Articles by Yankaskas, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aris, R. M.
Right arrow Articles by Yankaskas, J. R.

Am. J. Respir. Crit. Care Med., Vol 155, No. 5, May 1997, 1699-1704.

The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome

RM Aris, PH Gilligan, IP Neuringer, KK Gott, J Rea and JR Yankaskas
Department of Microbiology-Immunology, University of North Carolina at Chapel Hill, 27599-7524, USA.

The number of cystic fibrosis (CF) patients undergoing lung transplant continues to rise as long term survival improves. One major contraindication to this potentially life-saving intervention is infection with multi-drug-resistant bacteria. We undertook this retrospective study in 66 transplanted patients over 6 yr to determine the influence of panresistant bacteria on transplant outcome. The in vitro antibiotic susceptibility pattern of respiratory tract bacteria obtained pre- and/or intraoperatively was used to categorize patients into panresistant (n = 27) (Burkholderia cepacia, n = 6, and Pseudomonas aeruginosa, n = 21) or sensitive (n = 39) groups. Postoperative ventilator days, hospital length of stay, and antibiotic days were similar for both groups (p > 0.2). The incidence of bacterial bronchitis (28% and 33%, respectively) and pneumonia (28% and 38%, respectively) did not differ between these groups (p > 0.2) at 6 mo. Likewise, one-year (81% and 83%, respectively) survival was similar for both groups (p > 0.2). As expected, panresistant B. cepacia patients had a lower 1-yr survival (50% versus 90%, p < 0.05) and had a higher mortality attributable to B. cepacia (50% versus 0%, p < 0.01) compared with panresistant P. aeruginosa patients. Our results indicate that CF patients infected with panresistant P. aeruginosa have similar transplant outcomes as patients with sensitive bacteria and should not be excluded from lung transplant based solely on this criterion.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Murray, J. Charbeneau, B. C. Marshall, and J. J. LiPuma
Impact of Burkholderia Infection on Lung Transplantation in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 363 - 371.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G Meachery, A De Soyza, A Nicholson, G Parry, A Hasan, K Tocewicz, T Pillay, S Clark, J L Lordan, S Schueler, et al.
Outcomes of lung transplantation for cystic fibrosis in a large UK cohort
Thorax, August 1, 2008; 63(8): 725 - 731.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. M. Levine
A Survey of Clinical Practice of Lung Transplantation in North America
Chest, April 1, 2004; 125(4): 1224 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R.M. Kotloff and V.N. Ahya
Medical complications of lung transplantation
Eur. Respir. J., February 1, 2004; 23(2): 334 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A.R. Glanville and M. Estenne
Indications, patient selection and timing of referral for lung transplantation
Eur. Respir. J., November 1, 2003; 22(5): 845 - 852.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
T.M. Egan, F.C. Detterbeck, M.R. Mill, M.S. Bleiweis, R. Aris, L. Paradowski, G. Retsch-Bogart, and B.S. Mueller
Long term results of lung transplantation for cystic fibrosis
Eur. J. Cardiothorac. Surg., October 1, 2002; 22(4): 602 - 609.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. ARIS, J. C. ROUTH, J. J. LIPUMA, D. G. HEATH, and P. H. GILLIGAN
Lung Transplantation for Cystic Fibrosis Patients with Burkholderia cepacia Complex . Survival Linked to Genomovar Type
Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2102 - 2106.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
T. G. Liou, F. R. Adler, S. C. FitzSimmons, B. C. Cahill, J. R. Hibbs, and B. C. Marshall
Predictive 5-Year Survivorship Model of Cystic Fibrosis
Am. J. Epidemiol., February 15, 2001; 153(4): 345 - 352.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. CHAPARRO, J. MAURER, C. GUTIERREZ, M. KRAJDEN, C. CHAN, T. WINTON, S. KESHAVJEE, M. SCAVUZZO, E. TULLIS, M. HUTCHEON, et al.
Infection with Burkholderia cepacia in Cystic Fibrosis . Outcome Following Lung Transplantation
Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 43 - 48.
[Abstract] [Full Text]

Home page
 NEJMHome page
S. M. Arcasoy and R. M. Kotloff
Lung Transplantation
N. Engl. J. Med., April 8, 1999; 340(14): 1081 - 1091.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. M. Egan, F. C. Detterbeck, M. R. Mill, K. K. Gott, J. B. Rea, J. McSweeney, R. M. Aris, and L. J. Paradowski
Lung transplantation for cystic fibrosis: effective and durable therapy in a high-risk group
Ann. Thorac. Surg., August 1, 1998; 66(2): 337 - 346.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
International Guidelines for the Selection of Lung Transplant Candidates
Am. J. Respir. Crit. Care Med., July 1, 1998; 158(1): 335 - 339.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society